Berring-Uldum Amalie, Debes Nanette Marinette Monique, Pedersen Charlotte Reinhardt, Holst Helle
Ugeskr Laeger. 2018 May 7;180(19).
Treatment for insomnia with melatonin (MT) in children and adolescents aged 0-17 years has doubled since 2011. The efficacy and safety profile for MT in children has not been determined. Recent clinical trials indicate, that MT only has a clinical effect on sleep latency, not on total sleep time. Furthermore, it has emerged, that proper sleep hygiene can cure the sleep problem in 50% of the children. Typically, the safety evaluation only entails an unclassified report of adverse events. Two long-term studies investigate and dispel the potential influence of MT on puberty.
自2011年以来，0至17岁儿童和青少年使用褪黑素（MT）治疗失眠的情况增加了一倍。MT在儿童中的疗效和安全性尚未确定。最近的临床试验表明，MT仅对入睡潜伏期有临床作用，对总睡眠时间无作用。此外，已经发现，适当的睡眠卫生可以治愈50%儿童的睡眠问题。通常，安全性评估仅涉及不良事件的未分类报告。两项长期研究调查并消除了MT对青春期的潜在影响。
